Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 20/20 | 1.00 |
| ▸ | KCNA5 | P22460 | 16/20 | 1.00 |
| ▸ | KCNA4 | P22459 | 2/20 | 1.00 |
| ▸ | KCNA1 | Q09470 | 2/20 | 1.00 |
| ▸ | KCNN4 | O15554 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | KCNA2 | P16389 | 1/20 | 1.00 |
| ▸ | KCNA6 | P17658 | 1/20 | 1.00 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | KCNN1 | Q92952 | 1/20 | 1.00 |
| ▸ | KCNA7 | Q96RP8 | 1/20 | 1.00 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410610 | 1.00 | KCNA3 (1.00) | KCNA3KCNA5KCNA4KCNA1KCNN4 | |
| SCHEMBL2585444 | 0.99 | KCNA3 (1.00) | KCNA3KCNA5KCNA4KCNA1KCNN4 | |
| SCHEMBL2583446 | 0.97 | KCNA3 (1.00) | KCNA3KCNA5KCNA4KCNA1KCNN4 | |
| SCHEMBL2585423 | 0.95 | KCNA3 (1.00) | KCNA3KCNA5KCNA4KCNA1KCNN4 | |
| SCHEMBL2582557 | 0.94 | KCNA3 (0.98) | KCNA3KCNA5KCNA4KCNA1KCNN4 | |
| SCHEMBL2576641 | 0.93 | KCNA3 (1.00) | KCNA3KCNA5KCNA4KCNA1KCNN4 | |
| SCHEMBL2581526 | 0.88 | KCNA3 (1.00) | KCNA3KCNA5KCNA4KCNA1KCNN4 | |
| SCHEMBL29386652 | 0.88 | KCNA3 (1.00) | KCNA3KCNA5KCNA4KCNA1KCNN4 | |
| SCHEMBL2801777 | 0.88 | KCNA3 (1.00) | KCNA3KCNA5KCNA4KCNA1KCNN4 | |
| SCHEMBL2576615 | 0.88 | KCNA3 (1.00) | KCNA3KCNA5KCNA4KCNA1KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796674-B1 | 5-PHENOXYALKOXYPSORALENS AND METHODS FOR SELECTIVE INHIBITION OF THE VOLTAGE GATED KV1.3 POTASSIUM CHANNEL | UNIV CALIFORNIA (US) | 2016-02-03 | — | — | EP | claimed |
| EP-2400298-B1 | Single B-cell cultivation method and specific antibody production | HOFFMANN LA ROCHE (CH) | 2013-08-14 | — | — | EP | claimed |
| US-20100121059-A1 | 5-PHENOXYALKOXYPSORALENS AND METHODS FOR SELECTIVE INHIBITION OF THE VOLTAGE GATED Kv1.3 POTASSIUM CHANNEL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-13 | — | — | US | claimed |
| US-7557138-B2 | 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-07 | — | — | US | claimed |
| US-20060079535-A1 | 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-04-13 | — | — | US | claimed |
| EP-4747234-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | Muna Therapeutics ApS (DK) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747235-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | Muna Therapeutics ApS (DK) | 2026-05-27 | — | — | EP | disclosed |
| US-20250289837-A1 | MITOCHONDRIOTROPIC HETEROARYL BENZAMIDE POTASSIUM CHANNEL KV1.3 INHIBITORS | UNIV LJUBLJANI (SI) | 2025-09-18 | — | — | US | disclosed |
| EP-3893913-B1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FRED HUTCHINSON CANCER CENTER (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2025017105-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | MUNA THERAPEUTICS APS (DK) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025017103-A1 | KV1.3 POTASSIUM CHANNEL ANTAGONISTS | MUNA THERAPEUTICS APS (DK) | 2025-01-23 | — | — | WO | disclosed |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-11-07 | — | — | US | disclosed |
| US-20100121059-A1 | 5-PHENOXYALKOXYPSORALENS AND METHODS FOR SELECTIVE INHIBITION OF THE VOLTAGE GATED Kv1.3 POTASSIUM CHANNEL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-13 | — | — | US | disclosed |
| US-7557138-B2 | 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557138-B2 | 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557138-B2 | 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1796674-A4 | 5-PHENOXYALKOXYPSORALENS AND METHODS FOR SELECTIVE INHIBITION OF THE VOLTAGE GATED KV1.3 POTASSIUM CHANNEL | UNIV CALIFORNIA (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1796674-A2 | 5-PHENOXYALKOXYPSORALENS AND METHODS FOR SELECTIVE INHIBITION OF THE VOLTAGE GATED KV1.3 POTASSIUM CHANNEL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006041800-A2 | 5-PHENOXYALKOXYPSORALENS AND METHODS FOR SELECTIVE INHIBITION OF THE VOLTAGE GATED KV1.3 POTASSIUM CHANNEL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20060079535-A1 | 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289837-A1 | MITOCHONDRIOTROPIC HETEROARYL BENZAMIDE POTASSIUM CHANNEL KV1.3 INHIBITORS | KCNJ2, KCNN3, KCNA3 | KCNA3 3/4885KCNA5 21/4885KCNA4 60/4885 |
| US-20100121059-A1 | 5-PHENOXYALKOXYPSORALENS AND METHODS FOR SELECTIVE INHIBITION OF THE VOLTAGE GATED Kv1.3 POTASSIUM CHANNEL | KCNA3, KCNJ2, KCNQ1 | KCNA3 1/4885KCNA5 12/4885KCNA4 31/4885 |
| US-20060079535-A1 | 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel | KCNA3, KCNJ2, KCNQ1 | KCNA3 1/4885KCNA5 12/4885KCNA4 31/4885 |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | KCNA3 4228/4885KCNA5 4502/4885KCNA4 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.